- Home
- PRA vs ORIC Comparison
PRA vs ORIC Comparison
Compare PRA & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRA | ORIC |
|---|---|---|
| Founded | 1976 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PRA | ORIC |
|---|---|---|
| Price | $24.72 | $7.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $25.00 | $20.00 |
| AVG Volume (30 Days) | 625.3K | ★ 1.3M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $1,098,028,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.97 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.72 | $3.90 |
| 52 Week High | $24.85 | $14.93 |
Technical Indicators
Market Signals| Indicator | PRA | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 58.27 | 28.78 |
| Support Level | $23.88 | N/A |
| Resistance Level | N/A | $10.54 |
| Average True Range (ATR) | 0.14 | 0.95 |
| MACD | 0.00 | -0.25 |
| Stochastic Oscillator | 68.60 | 0.45 |
Price Performance
Historical ComparisonAbout PRA ProAssurance Corporation
ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in five segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.